After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 ...

Mylan shares were up more than 12 percent, at $20.78. Follow Michael J. de la Merced and Katie Thomas on Twitter: @m_delamerced and @katie_thomas.

Mylan NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the ...

Mylan’s planned combination with Upjohn is a bright spot for investors, but the difficulties of the U.S. generic-drug market remain a potential obstacle.

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Mylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus. The firm revealed that it has received an update from the US Food ...

Mylan Inc. CEO Heather Bresch testifies during a hearing before the House Oversight and Government... [+] Reform Committee September 21, 2016 on Capitol Hill in Washington, D.C. (Photo by Alex ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...